Abstract
Our understanding of inflammatory bowel diseases (IBD) is constantly evolving, and many new treatment options have emerged recently. This review critically examines the evidence for these new developments and aims to provide an overview for medical professionals involved in the care of patients with IBD. Proposed changes in the use of aminosalicylates, immunosuppressants and biological agents are described, and the evidence for several promising novel agents is reviewed.
| Original language | English |
|---|---|
| Pages (from-to) | 258-264 |
| Number of pages | 7 |
| Journal | Internal Medicine Journal |
| Volume | 40 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2010 |
| Externally published | Yes |